Genscript Biotech EBITDA per Share
The EBITDA per Share of Genscript Biotech (1548.HK) as of Sep 27, 2026 is 0.11 USD.
Get this data via API
Financial Data API
EBITDA per Share
0.11USD
YoY
20,988.15%
Last updated:
EBITDA per Share of Genscript Biotech is 2026 0.11 USD. EBITDA per Share of Genscript Biotech was 2025 0.00 USD. It decreases by 20,988.15% higher compared to the previous year.
The Genscript Biotech EBITDA per Share history
3 Years
10 Years
25 Years
Max
EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.00 USD
Jan 1, 2019
-0.07 USD
Jan 1, 2020
-0.10 USD
Jan 1, 2021
-0.24 USD
Jan 1, 2022
-0.03 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.11 USD
| YEAR | EBITDA per Share | YoY |
|---|---|---|
| 0.11USD | +20,988.15% | |
| 0.00USD | -65.65% | |
| 0.00USD | -105.96% | |
| -0.03USD | -88.79% | |
| -0.24USD | +126.20% | |
| -0.10USD | +49.76% | |
| -0.07USD | -2,040.71% | |
| 0.00USD | -84.43% | |
| 0.02USD | +58.39% | |
| 0.01USD | +63.62% | |
| 0.01USD | +52.48% | |
| 0.01USD | — |
Access this data via the Eulerpool API
Genscript Biotech Stock analysis
What does Genscript Biotech do? GenScript Biotech Corp. is a leading biotechnology company founded in Nanjing, China in 2002. Today, it is headquartered in New Jersey, USA and operates worldwide. Genscript Biotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genscript Biotech stock
EBITDA per Share of Genscript Biotech is 0.11 USD in 2026.
On Eulerpool you can find the complete historical development of EBITDA per Share Genscript Biotech since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
Income Statement — Genscript Biotech
All Key Metrics — Genscript Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth